Japanese Discovery Could Lead to New Mesothelioma Blood Test

mesothelioma blood test

A discovery in Japan could lead to a more effective mesothelioma blood test for mesothelioma diagnosis. Japanese scientists say they have found a better way to detect mesothelioma cells in the blood.  The scientists are experts in occupational health. Malignant mesothelioma is an occupational cancer because people can get it from working near asbestos. Mesothelioma diagnosis is challenging. But a powerful mesothelioma blood test could make it easier to find the asbestos cancer earlier. Treatment often works better when patients start it earlier. Circulating Tumor Cells in the Blood of Mesothelioma Patients No matter what kind of cancer a person has, their tumor releases some cells into the blood. Mesothelioma tumors are no exception. These circulating tumor cells (CTCs) are … Continue reading Japanese Discovery Could Lead to New Mesothelioma Blood Test »

Study Suggests Sugar Supplement Could Slow Growth of Mesothelioma

nutritional supplement fights cancer

A sugar supplement might be able to slow the growth of mesothelioma and others types of cancer. The sugar supplement is called mannose. Mannose occurs naturally in some fruits, including cranberries. It is also sold as a nutritional supplement. Researchers with Cancer Research UK and Worldwide Cancer Research say mannose slowed the growth of tumors in mice. The test mice had leukemia, bone cancer, ovarian cancer, or bowel cancer. In a new report in the journal Nature, the researchers say mannose made mouse tumors smaller. It also helped chemotherapy work better and helped some mice live longer. How Does Mannose Slow Tumor Growth? All cells in the body need glucose to grow. This includes cancer cells. Cancers like mesothelioma need … Continue reading Study Suggests Sugar Supplement Could Slow Growth of Mesothelioma »

Mesothelioma Surgery PD Comparison

operation for mesothelioma

Lung-sparing surgery is another name for pleurectomy/decortication (PD). In PD, surgeons take out as much mesothelioma cancer as they can without taking out one of the lungs. The other main type of mesothelioma surgery is called EPP (extrapleural pneumonectomy). In that surgery, doctors do take out a lung when they take out the mesothelioma tumor. Some studies say patients who have PD surgery live longer than people who have EPP. They may also have fewer problems after surgery. What is the New Clinical Trial? Researchers in Belgium and The Netherlands are running a test called EORTC 1205. EORTC 1205 is a clinical trial. Clinical trials test new drugs or treatments to see how well they work in people. Right now, … Continue reading Mesothelioma Surgery PD Comparison »

When Chemotherapy Fails: Apatinib May Offer Third-Line Option for Mesothelioma Patients

An investigational drug being developed in China may offer a third lifeline to mesothelioma patients whose cancer does not respond to other chemotherapy drugs. Apatinib, also called YN968D1, is a tyrosine kinase inhibitor that is thought to help prevent the formation of blood vessels that mesothelioma tumors need to grow and spread. Right now, there is no approved second-line treatment for pleural mesothelioma, let alone a third-line treatment. Chinese researchers at 363 Hospital in Cheng Du — along with mesothelioma patients around the world — are hoping that apatinib will change that. Mesothelioma Case Study The researchers are hanging their hopes on the case of a 58-year old woman who showed up at their hospital complaining that she had had … Continue reading When Chemotherapy Fails: Apatinib May Offer Third-Line Option for Mesothelioma Patients »

New Study Sheds Light on Genetic Origins of Malignant Mesothelioma

Scientists in Australia have made a big step forward in understanding how a genetic mutation appears to drive the development of cancers such as malignant mesothelioma. The gene in question is called p53. Also known as the “guardian of the genome” for its tumor-suppressing action, p53 has been found to be mutated in about half of all human cancers, including many cases of mesothelioma. Although the primary external cause of mesothelioma is exposure to asbestos, the mutated p53 gene helps explain why some asbestos-exposed cells suddenly become cancerous and are able to grow and spread, unchecked. It may also help scientists develop new, more effective mesothelioma treatments. Right now, the prognosis for mesothelioma is often very poor. The p53 Gene … Continue reading New Study Sheds Light on Genetic Origins of Malignant Mesothelioma »

This Subset of Mesothelioma Patients May Live Longer

A group of mesothelioma experts from around the world has identified a set of criteria linked with longer mesothelioma survival. They are hopeful that their research will help doctors identify mesothelioma patients who fall into this longer-living group and direct them to the special care they may need to stay healthier, longer. In a new article in the Journal of Clinical Oncology, some of the world’s leading mesothelioma researchers, including scientists from Stanford University, New York University Langone Medical Center, The University of Hawaii, the Hyogo College of Medicine in Japan, and the Mesothelioma Applied Research Foundation, say mesothelioma patients who meet these criteria should consider genetic counseling and cancer screening. Criteria for Improved Mesothelioma Outcomes The report was based … Continue reading This Subset of Mesothelioma Patients May Live Longer »

Meta-Analysis Finds Lung-Sparing Surgery the Best Option for Most Mesothelioma Patients

There is now more evidence to support the growing number of experts who favor lung-sparing P/D surgery over radical extrapleural pneumonectomy (EPP) for the treatment of malignant pleural mesothelioma. There has been an ongoing debate within the surgical community over which procedure carries the most benefit with the least risk. The late David Sugarbaker, MD, of Baylor St. Luke’s Medical Center in Houston was a pioneer of the EPP procedure, which involves removing not only the diseased pleural lining where mesothelioma tumors grow, but also the nearest lung, most of the diaphragm, the pericardium, and other at-risk tissues. But it turns out that, although Sugarbaker and his team were able to show a mesothelioma survival benefit with EPP, their results, … Continue reading Meta-Analysis Finds Lung-Sparing Surgery the Best Option for Most Mesothelioma Patients »

Ofev Fails to Boost Mesothelioma Survival in New Study

In the quest to develop new, more effective first-line treatments for malignant pleural mesothelioma, it now looks like Ofev (nintedanib) is out of the running. Phase III results of the LUME-Meso mesothelioma trial are in and they contain some disappointing news for mesothelioma patients and for the drug’s developer, Boehringer Ingelheim. The news is especially disappointing since the results of the Phase II portion of the trial, released last year, looked promising. At that time, researchers reported a survival gain of more than 5 months among the Ofev-treated mesothelioma patients and progression-free survival of four months. But further research did not support those results, as investigators announced to the world’s lung cancer experts at the IASLC 19th World Lung Cancer … Continue reading Ofev Fails to Boost Mesothelioma Survival in New Study »

A Less Formal Approach to Connecting Mesothelioma Patients and Researchers

immunotherapy research

Mesothelioma researchers in England are experimenting with an innovative way to connect patients and scientists in the quest for a cure. Malignant mesothelioma, the cancer most closely associated with asbestos exposure, is one of the world’s most deadly malignancies. Many patients diagnosed with mesothelioma are given only months to live. Increasingly, clinical research holds great promise for new ways of approaching diseases like mesothelioma, but understanding that research and its implications can be difficult, even when listening to the researchers directly. To bridge the gap, investigators with the June Hancock Mesothelioma Research Fund (JHMRF) in Sheffield, UK have introduced “Meet the Researchers” — a program designed to engage mesothelioma patients and researchers in a more informal way. Mesothelioma Research Can … Continue reading A Less Formal Approach to Connecting Mesothelioma Patients and Researchers »

How Doctors Break Bad News May Impact Mesothelioma Survival

For newly diagnosed mesothelioma patients, having a doctor who is too compassionate could have a negative impact on their survival. Researchers at France’s University of Lille made that seemingly counterintuitive observation as part of the first study of the prognostic role of physician empathy in cancer patients. The results, published in the Journal of Clinical Medicine, suggest that, rather than comforting patients, too much compassion and listening from the oncologist tends to make them worry more about their odds of survival. Physician Attitude and Mesothelioma Outcomes The study involved 179 patients who were diagnosed with lung cancer or pleural mesothelioma between January 2015 and March 2016. Both cancers are difficult to treat and often carry a poor prognosis. This is … Continue reading How Doctors Break Bad News May Impact Mesothelioma Survival »

Get your free copy of
“Surviving Mesothelioma” Today!